Eventide Asset Management - Q4 2021 holdings

$7.83 Billion is the total value of Eventide Asset Management's 146 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 27.8% .

 Value Shares↓ Weighting
BHVN BuyBIOHAVEN PHARMACTL HLDG CO L$225,319,000
+22.4%
1,635,000
+23.4%
2.88%
+18.6%
DT BuyDYNATRACE INC$165,458,000
-14.8%
2,741,641
+0.1%
2.11%
-17.5%
HUBS BuyHUBSPOT INC$158,613,000
-1.4%
240,633
+1.1%
2.03%
-4.4%
DLO BuyDLOCAL LTD$156,655,000
+468.5%
4,389,312
+769.1%
2.00%
+451.5%
TT BuyTRANE TECHNOLOGIES PLC$148,128,000
+34.1%
733,200
+14.6%
1.89%
+29.9%
RXDX BuyPROMETHEUS BIOSCIENCES INC$145,120,000
+70.5%
3,742,507
+0.8%
1.85%
+65.1%
ARGX BuyARGENX SEsponsored adr$144,453,000
+43.6%
412,500
+23.9%
1.85%
+39.2%
NEP BuyNEXTERA ENERGY PARTNERS LP$140,492,000
+21.7%
1,664,600
+8.7%
1.80%
+17.9%
GLBE BuyGLOBAL E ONLINE LTD$135,647,000
+295.1%
2,139,886
+347.5%
1.73%
+282.6%
TREX BuyTREX CO INC$133,680,000
+48.7%
990,000
+12.2%
1.71%
+44.0%
LOW BuyLOWES COS INC$132,109,000
+28.3%
511,100
+0.7%
1.69%
+24.3%
GNRC BuyGENERAC HLDGS INC$129,542,000
+0.4%
368,100
+16.6%
1.66%
-2.8%
DHI BuyD R HORTON INC$116,215,000
+31.1%
1,071,600
+1.5%
1.48%
+27.0%
ENTG BuyENTEGRIS INC$99,708,000
+11.5%
719,500
+1.3%
1.27%
+8.1%
SPT BuySPROUT SOCIAL INC$90,322,000
-25.6%
995,943
+0.0%
1.15%
-28.0%
GH BuyGUARDANT HEALTH INC$88,628,000
+298.3%
886,100
+397.8%
1.13%
+286.7%
DDOG BuyDATADOG INC$87,096,000
+27.0%
489,000
+0.8%
1.11%
+23.1%
BCYC BuyBICYCLE THERAPEUTICS PLCsponsored ads$76,907,000
+58.9%
1,263,471
+8.6%
0.98%
+54.1%
CCI BuyCROWN CASTLE INTL CORP NEW$69,552,000
+22.5%
333,200
+1.7%
0.89%
+18.7%
YETI BuyYETI HLDGS INC$66,504,000
+12.5%
802,900
+16.4%
0.85%
+9.0%
KNBE NewKNOWBE4 INCcl a$66,205,0002,886,000
+100.0%
0.85%
A BuyAGILENT TECHNOLOGIES INC$60,076,000
+18.3%
376,300
+16.8%
0.77%
+14.6%
HASI BuyHANNON ARMSTRONG SUST INFR C$56,902,000
+10.4%
1,071,200
+11.1%
0.73%
+6.9%
NRIX BuyNURIX THERAPEUTICS INC$54,137,000
+50.6%
1,870,000
+55.8%
0.69%
+46.0%
CWEN BuyCLEARWAY ENERGY INCcl c$53,440,000
+25.9%
1,483,200
+5.7%
0.68%
+22.0%
SMAR BuySMARTSHEET INC$52,511,000
+14.9%
678,000
+2.1%
0.67%
+11.3%
XMTR BuyXOMETRY INC$48,894,000
+14.1%
954,030
+28.4%
0.62%
+10.6%
CLDX BuyCELLDEX THERAPEUTICS INC NEW$47,871,000
-21.4%
1,238,900
+9.8%
0.61%
-23.8%
EPIX BuyESSA PHARMA INC$47,125,000
+170.1%
3,318,647
+52.2%
0.60%
+161.7%
MRTX BuyMIRATI THERAPEUTICS INC$42,779,000
+86.8%
291,626
+125.2%
0.55%
+81.1%
COUR BuyCOURSERA INC$42,482,000
+67.8%
1,738,228
+117.3%
0.54%
+62.6%
BPMC BuyBLUEPRINT MEDICINES CORP$42,394,000
+15.8%
395,800
+11.2%
0.54%
+12.2%
MPWR BuyMONOLITHIC PWR SYS INC$42,011,000
+11.9%
85,157
+9.9%
0.54%
+8.5%
STRO BuySUTRO BIOPHARMA INC$40,310,000
-10.0%
2,708,975
+14.3%
0.52%
-12.9%
ADCT BuyADC THERAPEUTICS SA$39,895,000
+12.0%
1,975,000
+50.5%
0.51%
+8.5%
NCNO BuyNCINO INC$37,744,000
-19.8%
688,000
+3.8%
0.48%
-22.4%
MASS Buy908 DEVICES INC$36,477,000
+64.4%
1,410,000
+106.7%
0.47%
+59.0%
LSCC BuyLATTICE SEMICONDUCTOR CORP$36,353,000
+862.0%
471,744
+707.1%
0.46%
+830.0%
ANNX BuyANNEXON INC$32,747,000
-30.5%
2,850,000
+12.6%
0.42%
-32.7%
NVT BuyNVENT ELECTRIC PLC$31,624,000
+26.7%
832,200
+7.8%
0.40%
+22.8%
COGT NewCOGENT BIOSCIENCES INC$30,158,0003,514,909
+100.0%
0.38%
NewDUOLINGO INC$27,323,000257,500
+100.0%
0.35%
PLD BuyPROLOGIS INC.$27,039,000
+47.2%
160,600
+9.6%
0.35%
+43.0%
ISRG BuyINTUITIVE SURGICAL INC$26,948,000
+8.4%
75,000
+200.0%
0.34%
+4.9%
REXR BuyREXFORD INDL RLTY INC$23,958,000
+125.0%
295,374
+57.4%
0.31%
+118.6%
PNR BuyPENTAIR PLC$23,866,000
+37.4%
326,800
+36.6%
0.30%
+33.2%
LOB BuyLIVE OAK BANCSHARES INC$23,230,000
+41.0%
266,128
+2.8%
0.30%
+36.9%
ESI BuyELEMENT SOLUTIONS INC$22,670,000
+123.4%
933,700
+99.5%
0.29%
+116.4%
NDAQ BuyNASDAQ INC$22,261,000
+33.9%
106,000
+23.1%
0.28%
+29.7%
ELS BuyEQUITY LIFESTYLE PPTYS INC$20,004,000
+30.1%
228,200
+16.0%
0.26%
+26.1%
SNV BuySYNOVUS FINL CORP$18,382,000
+189.3%
384,000
+165.2%
0.24%
+179.8%
APTVPRA NewAPTIV PLC5.5% cnv pfd a added$16,098,00087,500
+100.0%
0.21%
IEX BuyIDEX CORP$13,801,000
+45.9%
58,400
+27.8%
0.18%
+40.8%
ENPH NewENPHASE ENERGY INC$12,166,00066,500
+100.0%
0.16%
SYY BuySYSCO CORP$10,321,000
+45.6%
131,398
+45.5%
0.13%
+41.9%
GRMN BuyGARMIN LTD$8,306,000
+19.0%
61,000
+35.9%
0.11%
+15.2%
WMB NewWILLIAMS COS INC$7,523,000288,900
+100.0%
0.10%
IMGN NewIMMUNOGEN INC$7,420,0001,000,000
+100.0%
0.10%
BOLT BuyBOLT BIOTHERAPEUTICS INC$7,103,000
+5.2%
1,449,494
+171.4%
0.09%
+2.2%
EGP NewEASTGROUP PPTYS INC$6,881,00030,200
+100.0%
0.09%
NewROIVANT SCIENCES LTD$6,703,000700,000
+100.0%
0.09%
LNG NewCHENIERE ENERGY INC$6,684,00065,900
+100.0%
0.08%
BRKS NewAZENTA INC$6,589,00063,900
+100.0%
0.08%
ICPT NewINTERCEPT PHARMACEUTICALS IN$5,334,000327,444
+100.0%
0.07%
FOUR BuySHIFT4 PMTS INCcl a$5,156,000
+34.1%
89,000
+79.4%
0.07%
+29.4%
NewARTERIS INC$3,805,000180,259
+100.0%
0.05%
OM BuyOUTSET MED INC$3,180,000
-0.1%
69,000
+7.1%
0.04%
-2.4%
NewGUARDANT HEALTH INCnote 11/1$2,948,0002,900,000
+100.0%
0.04%
NewPLANET LABS PBC$953,000155,000
+100.0%
0.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-14
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q4 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings